Business
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in February.\n\n \n \n \n \n \n \n\n \nPiper Sandler Biopharma Mogul SummitFebruary 2-4, 2025, Park City, UtahTrevi Representative: Lisa Delfini, Chief Financial Officer\nOppenheimer Healthcare 2025 Winter CEO & Investor SummitFebruary 3-6, 2025, Vail, ColoradoTrevi Representative: Jennifer Good, President and CEO\nOppenheimer 35th Annual Healthcare Life Sciences Virtual Conference February 11-12, 2025Corporate Presentation: February 11, 9:20 - 9:50 am ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Chief Development OfficerRegister here to watch the live presentation\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\nChronic cough is a highly prevalent disease in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current off-label treatment options provide minimal benefit to patients. \nRefractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersens...